News for RegeneRx Biopharmaceuticals, Inc. (RGRX)

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue...

ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. , a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that,...

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

ROCKVILLE, Md., April 11, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. , a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a... | April 11, 2023

ROCKVILLE, Md., Jan. 31, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. , a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting... | January 31, 2023

Read RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Shares Pass Below 50-Day Moving Average of $0.17 at ETF Daily News

Expect ARISE-4 Trial to Begin Around 2nd Quarter of 2023 ROCKVILLE, Md., Oct. 24, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. , a clinical-stage drug development company focused on... | October 24, 2022

Read RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Stock Price Crosses Below Fifty Day Moving Average of $0.17 at ETF Daily News

Read RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Shares Pass Below Fifty Day Moving Average of $0.17 at ETF Daily News

First of Two Phase 3 NK Trials Expected to Start in November 2022 ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. , a clinical-stage drug development company... | September 27, 2022

/PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter...